title: Interactions between IL-4, anti-CD40, and anti-immunoglobulin as activators of locomotion of human B cells.
abstract: The locomotor properties of small, surface IgM+ and surface IgD+ B cells from the human tonsil were studied using polarization assays and collagen gel invasion assays. These cells gave poor locomotor responses when freshly isolated from the tonsil; but 30 to 40% of the cells polarized and invaded collagen gels after overnight culture in IL-4 or anti-CD40. IL-13 had a similar but weaker effect. Culture with anti-CD40 and IL-4 together gave a higher proportion of polarized cells than either alone, and culture in anti-CD40, IL-4, and anti-IgM gave a still higher proportion (> 60% of B cells polarized). Polarization increased gradually, during hours of culture, unlike the typical rapid response to chemoattractants. We also studied the immediate (< 30 min) effects of chemoattractants on B cell polarization. B cells cultured overnight then washed, but not B cells fresh from the tonsil, polarized immediately in response to anti-CD40. Similar responses to anti-IgM and anti-IgD, both pre- and postculture were also observed, but the response of cultured cells was stronger. IL-4-cultured B cells invaded collagen gels incorporating anti-IgM, anti-IgD, or anti-CD40 in higher numbers than control gels. Most of the invading cells were surface IgM+. These results suggest that locomotor activation in B cells requires two steps. The capacity for locomotion is growth-related and is first activated by IL-4 or by anti-CD40, enhanced by the presence of anti-IgM. Following activation, the cells respond rapidly to chemoattractants such as anti-Ig or anti-CD40.
authors.affiliation: Department of Immunology, University of Glasgow Western Infirmary, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Komai-Koma
authors.forename: F Y
authors.initials: FY
authors.lastname: Liew
authors.forename: P C
authors.initials: PC
authors.lastname: Wilkinson
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology*; D015703:Antigens, CD / Q000502:physiology*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000502:physiology*; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D019013:CD40 Antigens; D002465:Cell Movement; D016764:Cell Polarity; D048429:Cell Size; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003094:Collagen; D005782:Gels; D006801:Humans; D007072:Immunoglobulin D / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D015847:Interleukin-4 / Q000494:pharmacology*; D014066:Palatine Tonsil / Q000166:cytology; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D019013:CD40 Antigens; D005782:Gels; D007072:Immunoglobulin D; D007075:Immunoglobulin M; D011947:Receptors, Antigen, B-Cell; D011994:Recombinant Proteins; C044203:anti-IgM; D015847:Interleukin-4; D003094:Collagen